Peter C. Black, MD, presented “Use of Biomarkers in NMIBC: What’s New and What Should We Use?” at the 6th International Bladder Cancer Update on November 19, 2022, in Scottsdale, Arizona.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Black, Peter C. “Use of Biomarkers in NMIBC: What’s New and What Should We Use?” November 2022. Accessed Dec 2022. https://grandroundsinurology.com/use-of-biomarkers-in-nmibc-whats-new-and-what-should-we-use/
Use of Biomarkers in NMIBC: What’s New and What Should We Use?
Dr. Peter C. Black moderated an insightful panel discussion exploring the latest advancements in the use of biomarkers for non-muscle invasive bladder cancer (NMIBC) and their potential integration into clinical practice. The panel discussed significant progress in identifying and validating biomarkers for NMIBC. These biomarkers play a crucial role in early detection, prognosis, and monitoring treatment response. Advances in molecular and genetic profiling techniques have enabled the discovery of more precise and reliable biomarkers.
The discussion emphasized the practical application of these new biomarkers in clinical settings. Panelists examined various biomarkers currently in use, such as urine-based tests, and their ability to improve diagnostic accuracy and treatment planning. They also explored the role of biomarkers in personalized medicine, allowing for treatment approaches tailored to individual patient profiles. The future of NMIBC treatment appears promising with the potential integration of these novel biomarkers, leading to better patient outcomes and more efficient treatment protocols.
The panel addressed challenges in incorporating biomarkers into routine clinical practice, such as cost, accessibility, and the need for standardized protocols. Emphasis was placed on the importance of multidisciplinary collaboration and continuous education for healthcare professionals to ensure successful implementation.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Dr. Peter Black is a urologic oncologist at Vancouver General Hospital, a research scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia (UBC). He received his undergraduate degree from UBC and his medical degree from Johannes Gutenberg University in Mainz, Germany. He completed his urologic training at the University of Washington in Seattle and a Fellowship in Urologic Oncology at MD Anderson Cancer Center in Houston, Texas. He has a clinical subspecialty interest in bladder cancer. He maintains a grant-funded translational research program in urothelial carcinoma and is an active cancer clinical trialist in this field.
